In May 2021, the Italian Competition Authority (AGCM or ICA) launched an investigation into restrictions on resale prices that a pharmaceutical company, SOFAR, was alleged to have imposed upon its distribution network for a probiotic product (Enterolactis Plus). In Europe, agreements or anomalous inducements between suppliers and distributors aimed at restricting the freedom of the latter to set their own resale prices (known as Resale Price Maintenance or “RPM”) constitute “hardcore” infringement of Article 101 of the
Access to this article is restricted to subscribers
Already Subscribed? Sign-in
Access to this article is restricted to subscribers.
Read one article for free
Sign-up to read this article for free and discover our services.